). Individual reprints of this article and a bound booklet of the entire Symposium on Oncology Practice: Hematological Malignancies will be available for purchase from our Web site www.mayoclinicproceedings.com.
Myeloid disorders constitute a subgroup of hematological malignancies that is separate from lymphoid disorders. The World Health Organization system for classification of tumors of the hematopoietic system divides myeloid disorders into acute myeloid leukemia and chronic myeloid disorders based on the presence or absence, respectively, of acute myeloid leukemiadefining morphological and cytogenetic features including the presence of 20% or more myeloblasts in either the bone marrow or the peripheral blood. A recently proposed semimolecular classification system for chronic myeloid disorders recognizes 3 broad categories: the myelodysplastic syndrome, classic myeloproliferative disorders (MPD), and atypical MPD. Classic MPD includes polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, and chronic myeloid leukemia. Both myelodysplastic syndrome and BCR/ABL-negative classic MPD were previously discussed as part of the current ongoing symposium on hematological malignancies. The current review focuses on the diagnosis and treatment of both molecularly defined and clinicopathologically assigned categories of atypical MPD: chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, chronic neutrophilic leukemia, chronic basophilic leukemia, chronic eosinophilic leukemia, idiopathic eosinophilia including hypereosinophilic syndrome, systemic mastocytosis, unclassified MPD, and eosinophilic/mast cell disorders associated with mutations of platelet-derived growth factor receptors α α α α α (PDGFRA) and β β β β β (PDGFRB), FGFR1, and KIT.
Mayo Clin Proc. 2006;81(4):553-563 AML = acute myeloid leukemia; ASCT = allogeneic stem cell transplantation; CEL = chronic eosinophilic leukemia; CMD = chronic myeloid disorders; CML = chronic myeloid leukemia; CMML = chronic myelomonocytic leukemia; CNL = chronic neutrophilic leukemia; EMS = 8p11 myeloproliferative syndrome; ET = essential thrombocythemia; FGFR 1 = fibroblast growth factor receptor 1; FISH = fluorescence in situ hybridization; HES = hypereosinophilic syndrome; IL = interleukin; JMML = juvenile myelomonocytic leukemia; MDS = myelodysplastic syndrome; MMM = myelofibrosis with myeloid metaplasia; MPD = myeloproliferative disorders; NF1 = neurofibromatosis type 1; PCPD = plasma cell proliferative disorders; PDGFR = platelet-derived growth factor receptors; PV = polcythemia vera; SM = systemic mastocytosis; UMPD = unclassified MPD; WHO = World Health Organization T he term myeloproliferative disorders (MPD) was first introduced by Dr William Dameshek in 1951 to emphasize the clinicopathological similarities between chronic myeloid leukemia (CML), essential thrombocythemia, (ET), polycythemia vera, (PV), and with myeloid metaplasia (MMM) (aka, chronic idiopathic myelofibrosis or primary myelofibrosis).
1 Accordingly, these 4 disorders are currently referred to as "classic" MPD. However, several MPD-like clinicopathological entities have since been described and, at present, the World Health Organization (WHO) system for classification of myeloid neoplasms organizes MPD and the related chronic myeloid disorders (CMD) into 4 broad categories: myelodysplastic syndrome (MDS), MPD, MDS/MPD, and systemic mastocytosis (SM). 2 The WHO MPD category includes the 4 classic MPD (CML, ET, PV, MMM) as well as chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), and unclassified MPD (UMPD). On the other hand, the MDS/MPD category includes chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and the so called atypical CML. In contrast to the WHO classification scheme, an alternative semimolecular classification system organizes CMD first into MDS and MPD and subsequently subdivides MPD into classic and atypical variants (Table 1) . In other words, the latter system treats classic MPD as a completely separate category, an action supported by both historical connotation and the presence of fundamental differences in disease biology. 3 Both classic and atypical MPD represent stem cell-derived clonal myeloproliferation, and the primary clonogenic mutation has been identified in some of the disease subentities. 4 This has allowed further classification of "atypical" MPD into "molecularly defined" and "clinicopathologically assigned" disease categories (Table 1) .
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MOLECULARLY DEFINED ATYPICAL MYELOPROLIFERATIVE DISORDERS
PDGFRA-REARRANGED EOSINOPHILIC DISORDERS
Blood eosinophilia represents either a primary or secondary process depending on the respective absence or presence of conditions known to be associated with reactive eosinophilia. 6 Primary eosinophilia is in turn subclassified into clonal or idiopathic eosinophilia depending on the respective presence or absence of either a cytogenetic abnormality or bone marrow histological evidence of an otherwise defined acute leukemia or CMD. 6 Hematological disorders that can be accompanied by clonal eosinophilia include acute myeloid leukemia (AML), 7 acute lymphocytic leukemia, 8 
Myelodysplastic syndrome (MDS)
Diagnosis of MDS is considered in the presence of erythroid and other myeloid dysplasia and the absence of peripheral blood monocytosis (monocyte count, ≥1 × 10 9 /L). Diagnosis also requires the absence of 20% blasts or more in either the bone marrow or peripheral blood
Myeloproliferative disorders (MPD)
Diagnosis of MPD is currently operational and requires the exclusion of both MDS and acute leukemia. Clinical phenotype in MPD is markedly variable, and in some instances, the disease-causing mutation has been identified. The term myeloproliferative disorder was first coined by Dr William Dameshek in 1951 and at that time included polycythemia vera (PV), essential thrombocythemia (ET) myelofibrosis with myeloid metaplasia (MMM), and chronic myeloid leukemic (CML). Accordingly, these 4 disorders are now classified as classic MPD, and all other MPD-like diseases are operationally labeled as atypical MPD. Both classic and atypical MPD are subsequently divided into molecularly defined and clinicopathologically assigned categories depending on whether the disease-causing mutation is known Classic MPD I. Molecularly defined At present, only 1 (ie, CML) of the 4 classic MPD is molecularly defined. However, CML can mimic both other classic or atypical MPD in its presentation. Therefore, the first step in the diagnostic evaluation of a chronic myeloid disorder is to perform mutation screening for BCR/ABL with cytogenetic and fluorescence in situ hybridization studies. The absence of the mutation rules out the possibility of CML, and its presence, in the context of a chronic myeloid process, is diagnostic of CML II. Clinicopathologically assigned Currently, no molecular marker is diagnostic of the other 3 classic MPD, including PV, ET, and MMM. Their diagnosis is currently based on consensus-defined bone marrow and clinical criteria. Most recently, a new mutation, JAK2
V617F
, was described in almost all patients with PV and half of those with either ET or MMM. As a result, modern diagnostic criteria for these disorders incorporate screening for the specific JAK2 mutation
Atypical MPD
The atypical MPD category includes all chronic myeloid disorders that cannot be clearly classified as either MDS or classic MPD. Similar to the case with CML, the oncogenic mutation in some of the entities included in this category has been characterized I. Molecularly defined atypical MPD Most cases with molecularly defined atypical MPD are accompanied by prominent blood eosinophilia and involve mutations that affect either 1 of the 2 platelet-derived growth factor receptors PDGFR (α and β) or the fibroblast growth factor receptor 1. It is unusual to detect these mutations in the absence of eosinophilia. Recent studies have revealed an invariable association between activating mutations of the genes for both plateletderived growth factor receptors α (PDGFRA) and β (PDGFRB) and clonal eosinophilia that accompanies a subset of patients with an HES, SM, CEL, CMML, or UMPD phenotype.
13-16 PDGFRA-rearrangement usually occurs as a result of a small (~800 bp) interstitial deletion involving the chromosome 4q12 region and resulting in the fusion of the PDGFRA gene to the centromeric FIP1L1 gene (FIP1L1-PDGFRA). 13 However, PDGFRA can also be activated by a chromosomal translocation such as t(4;22)(q12;q11) that produces BCR/PDGFRA fusion. [17] [18] [19] Either way, the protein product of the altered gene is a constitutively activated receptor tyrosine kinase (PDGFRA) that has been shown to transform hematopoietic cells and produce an MPD disease phenotype in mice. 13, 20, 21 To date, FIP1L1-PDGFRA has been demonstrated in patients with the clinical phenotypes of HES, 13 SM, 22 and CEL. 23 However, on close scrutiny, all such cases might represent a subset of patients with eosinophilia-associated SM. 22 In a systematic study of prevalence and clinicopathologic correlation, FIP1L1-PDGFRA was detected by fluorescence in situ hybridization (FISH) in approximately 14% of patients with primary eosinophilia, and almost all such cases were histologically classified as SM. 22 Therefore, the contemporary nomenclature for the disease associated with FIP1L1-PDGFRA is SM-CEL.
The diagnosis of FIP1L1-PDGFRA + SM-CEL should be suspected in any patient who presents with a disease phenotype that suggests HES, eosinophilia-associated SM, or CEL. Either peripheral blood or bone marrow screening for the FIP1L1-PDGFRA abnormality should be done in all such cases. Of note, standard cytogenetic methods are not capable of revealing the FIP1L1-PDGFRA abnormality. This must be sought with either a FISH or reverse transcriptase-polymerase chain reaction-based laboratory technique.
13,14
With rare exceptions, 23 all patients described so far with FIP1L1-PDGFRA + SM-CEL have been males. [23] [24] [25] The most relevant aspect of FIP1L1-PDGFRA + SM-CEL is its exquisite sensitivity to treatment with imatinib mesylate. 13, 19, 22, 24, 26 In one of the largest studies to date of imatinib therapy for FIP1L1-PDGFRA + SM-CEL, all 8 treated patients achieved complete and durable remissions with relatively low drug dosage levels (100 mg/d).
14,22,27 A similar experience has been reported with PDGFRA rearrangements resulting from cytogenetic translocations involving chromosome 4q12; t(4;22)(q12;q11.2).
17,19 Treatment with imatinib is recommended even in the absence of symptoms because of the potential to prevent cardiovascular complications.
24,28,29 Finally, imatinib therapy for FIP1L1-PDGFRA + SM-CEL has been associated with drug-induced cardiogenic shock that might be prevented by the concomitant use of systemic corticosteroid therapy (1 mg/ kg per day) during the initial 1 or 2 weeks of imatinib therapy.
30
PDGFRB-REARRANGED EOSINOPHILIC DISORDERS
The PDGFRB gene is located on chromosome 5q33 and when activated by various chromosomal translocations involving 5q33 and other partner chromosomes, such as t(5;12)(q33;p13), produces a rare MPD that is usually associated with prominent eosinophilia and sometimes with monocytosis.
31 Accordingly, the clinical phenotypes associated with PDGFRB-rearranged MPD have included both CMML and CEL.
7,15,31-34 Similar to the case with FIP1L1-PDGFRA + SM-CEL, women are rarely affected with PDGFRB-rearranged MPD, and imatinib is therapeutically effective. Imatinib drug dosages used in this instance have been higher (400 mg/d), and it is currently unknown if lower doses would have the same effect.
15 Diagnosis should be suspected in the presence of an abnormal karyotype that involves a 5q33 chromosomal translocation, whereas it is unusual to encounter karyotypically occult cases.
11,15,35-37 Finally, it is underscored that both PDGFRBrearranged MPD and FIP1L1-PDGFRA + SM-CEL are relatively rare disorders, and clinicians should refrain from the indiscriminate use of imatinib therapy for primary eosinophilia or SM.
38,39
8P11 MYELOPROLIFERATIVE SYNDROME The 8p11 myeloproliferative syndrome (EMS), also known as human stem cell leukemia/lymphoma syndrome, is associated with fibroblast growth factor receptor 1 (FGFR1) rearrangement that results from cytogenetic translocations involving chromosome 8p11 and multiple other partner chromosomes, which juxtaposes the tyrosine kinase domain of FGFR1 to a dimerization domain from the partner gene, resulting in constitutive kinase activation. 40 The clinical phenotype includes eosinophilia, both myeloproliferative and myelodysplastic features, lymphadenopathy, and a high incidence of T-cell nonHodgkin lymphoma with progression to AML. 40, 41 As is the case with PDGFRB-rearranged MPD, diagnosis is facilitated by the fact that EMS is often karyotypically apparent. On the other hand, currently available treatment agents, including imatinib, are ineffective in EMS, and patients are best served by referral for participation in clinical trials.
SM ASSOCIATED WITH KIT MUTATION
Systemic mastocytosis, as is the case with most MPD, is a clonal stem cell disorder that is clinically characterized by urticaria pigmentosa, mast cell mediator release symptoms (diarrhea, urticaria, pruritus, flushing, syncope), osteoporosis, hepatosplenomegaly, ascites, and cytopenia. At least 2 genes (KIT and PDGFRA) are involved in mutations that are currently considered pathogenetically relevant in SM. Most"molecularly defined" SM is linked to activating KIT mutations involving the kinase, juxtamembrane, or transmembrane domains, and their distinction is therapeutically relevant.
42-47 For example, wild-type KIT is inhibited by imatinib, whereas such drug sensitivity is displayed by some (eg, V560G) but not other (eg, D816V) mutant KIT.
42,48-50 Accordingly, imatinib is used as first line therapy in SM associated with either PDGFRA or non-D816V KIT mutations, whereas it is unlikely to be effective in KIT D816V -positive cases. In the latter instance, treatment is similar to that of molecularly undefined SM; cytoreductive therapy is not recommended for indolent SM, whereas either interferon alfa or cladribine is used as first-line therapy for aggressive disease. [51] [52] [53] We await with great interest the results from currently ongoing treatment studies in SM that use second-generation kinase inhibitors including dasatinib and AMN107. The former but not the latter drug displays in vitro activity against KIT D816V -positive mast cell lines and primary cells. 54 At present, in most places, mutation screening for KIT is available only in a research setting.
CLINICOPATHOLOGICALLY ASSIGNED ATYPICAL MYELOPROLIFERATIVE DISORDERS
CHRONIC NEUTROPHILIC LEUKEMIA Chronic neutrophilic leukemia (CNL) is characterized by mature neutrophilic leukocytosis with few or no circulating immature granulocytes, monocytosis, or basophilia. 55 Affected patients usually have splenomegaly, and bone marrow histology reveals granulocytic hyperplasia without evidence of dysplasia or substantial reticulin fibrosis. 56, 57 Both cytogenetic and molecular analysis are negative for BCR/ABL. In addition, diagnosis of CNL requires the absence of typical features that are characteristic of other MPD. 58 The disease is rare, with approximately 150 reported cases to date. 59 Median age at diagnosis is approximately 67 years, and the disease is equally prevalent in both sexes. Most patients are asymptomatic at diagnosis. Fatigue is the most common presenting symptom. Other reported symptoms include weight loss, easy bruising, bone pain, and night sweats. Most patients have palpable splenomegaly at diagnosis.
By definition, patients with CNL feature "right-shifted" neutrophilia with less than 5% immature granulocytes (promyelocytes, myelocytes, and metamyelocytes). Diagnosis requires the absence of circulating blasts, absolute or relative monocytosis, eosinophilia, or basophilia. Most patients are mildly anemic at presentation, and the platelet count is often normal. However, later in the clinical course, thrombocytopenia accompanies progressive splenomegaly. The leukocyte alkaline phosphatase score is elevated in most patients. Bone marrow examination reveals hypercellular marrow with relatively mature granulocytic hyperplasia without excess blasts, dysplasia, or Auer rods. Cytogenetic study results are abnormal in approximately 23% of patients at diagnosis, and specific lesions have included 20q-, 21+, 11q-, and trisomy 9.
60-62
The differential diagnosis of CNL includes reactive leukocytosis, plasma cell proliferative disorders (PCPD), and other MPD. Reactive leukocytosis might accompany chronic infections and inflammatory or malignant conditions. 63, 64 Interestingly, the incidence of PCPD in CNL has been reported to be as high as 32%. 65 It is currently thought that neutrophilia seen in association with PCPD represents a reactive phenomenon, [66] [67] [68] and current CNL diagnosis therefore requires the absence of clonal plasma cells in either the peripheral blood or the bone marrow or, if present, the confirmation of myeloid cell clonality by cytogenetic or molecular studies. 58, 69 Similarly, the possibility of otherwise defined CMD, including neutrophilic CML, 70 must be excluded before a working diagnosis of CNL is made.
The disease course is heterogeneous and includes a clinically indolent chronic phase followed over a variable period by an accelerated or blast phase. Disease acceleration is heralded by progressive treatment-refractory neutrophilia, marked splenomegaly, anemia, thrombocytopenia, and the appearance of immature myeloid progenitor cells, including myeloblasts, in the peripheral blood. Median survival is approximately 2 years, and causes of death include blast transformation (always myeloid), progressive disease without blast transformation, bleeding, and infection.
Treatment reports of CNL have included splenic irradiation, splenectomy, cytoreductive agents including hydroxyurea, busulfan, 6-thioguanine, low-dose cytarabine, cladribine, AML-like induction chemotherapy, and allogeneic stem cell transplantation (ASCT). In general, we do not recommend splenectomy because of the potential for exacerbating leukocytosis. 71 Based on anecdotal experience, we favor the use of hydroxyurea as first-line therapy and expect response in 75% of patients with either leukocytosis or splenomegaly. Responses often last for a median of 12 months. For second-line treatment, we use interferon alfa based on reports of successful use in a small number of patients. [72] [73] [74] Acute myeloid leukemia-like induction chemotherapy is ineffective in CNL, whereas ASCT is a potentially curative treatment modality for transplant-eligible recipients who are still in chronic phase. cally assigned myeloid malignancy such as acute leukemia, MDS, classic MPD, SM, or CMML. 76, 77 We prefer to use the term strictly in patients with an "HES" phenotype who also display either a clonal cytogenetic/molecular abnormality or excess blasts in the bone marrow or peripheral blood. 77, 78 The WHO defines CEL in the presence of a blood eosinophil count that is 1.5 × 10 9 /L or higher accompanied by either the presence of myeloblast excess (either >2% in the peripheral blood or 5%-19% in the bone marrow) or evidence of myeloid clonality. 79 The distinction between CEL and UMPD associated with eosinophilia can be challenging and is arbitrarily based on the prominent myeloproliferative component seen in the latter instance.
12,76,77 Reported cytogenetic abnormalities in CEL, other than those associated with molecularly defined eosinophilic disorders, include trisomy 8 (the most frequent), t(10;11)(p14;q21), and t(7;12)(q11;p11).
12, 76, 78 In general, molecularly undefined CEL does not respond to imatinib, and treatment strategies are often not different from those used in other similar MPD: ASCT for transplant-eligible recipients with poor risk factors and participation in experimental treatment protocols otherwise.
HYPEREOSINOPHILIC SYNDROME Blood eosinophilia that is neither secondary nor clonal is operationally labeled as "idiopathic." Hypereosinophilic syndrome is a subcategory of idiopathic eosinophilia that requires documentation of both a target organ damage and an absolute eosinophil count of 1.5 × 10 9 /L or higher for at least 6 months. [79] [80] [81] Many patients with idiopathic eosinophilia are asymptomatic at diagnosis, whereas HES requires, by definition, the presence of eosinophilia-associated tissue damage, including cardiomyopathy, gastroenteritis, cutaneous lesions, sinusitis, pneumonitis, neuritis, and vasculitis. In addition, some patients manifest thromboembolic complications, hepatosplenomegaly, and either cytopenia or cytosis. An HES phenotype with episodic angioedema, urticaria, fever, weight gain, and elevated levels of serum IgE, IgM, and polyclonal γ globulins is associated with a relatively benign, corticosteroid-responsive disease (Gleich syndrome). 82 In the strict sense, true HES should be devoid of any molecular or cytogenetic marker of clonality. 76 In addition, the bone marrow histology in true HES must not display an abnormal population of mast cells, monocytosis, or evidence of trilineage myeloproliferation or dysplasia. 76 Therefore, both bone marrow histological and cytogenetic/ molecular studies should be performed before a working diagnosis of HES is made. Additional blood studies that are currently recommended during the evaluation of possible HES include serum tryptase (an increased level suggests SM and warrants molecular studies to detect FIP1L1-PDGFRA), 22, 83 T-cell immunophenotyping and T-cell receptor antigen gene rearrangement analysis (a positive test suggests an underlying clonal or phenotypically abnormal T-cell disorder and warrants measurement of interleukin (IL)-5 as well as consideration of T-cell-directed therapy), 84 ,85 serum IL-5 (an elevated level requires careful evaluation of the bone marrow as well as T-cell gene rearrangement studies for the presence of a clonal T-cell disease), 84 and serum IgE level (patients with an increased IgE level might be at a lower risk of developing eosinophilia-associated heart disease). 86 In addition, initial evaluation in HES should include an echocardiogram and measurement of serum troponin levels to screen for myocardial involvement by the disease. 87 Specific therapy for HES is indicated in the presence of eosinophil-mediated tissue injury, and first-line therapy in this regard is prednisone alone (1 mg/kg per day) or in combination with hydroxyurea (starting dosage, 500 mg twice daily). 88, 89 In corticosteroidrefractory or corticosteroid-dependent patients, interferon alfa (starting dosage, 1 million units 3 times a week) is currently considered second-line treatment of choice. [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] Modern treatment considerations for patients with HES who are refractory to conventional therapy include imatinib, 13, 104 mepolizumab (monoclonal antibody to IL-5), 28,87,105-107 and alemtuzumab (monoclonal antibody to CD52). 108, 109 In drugrefractory cases, ASCT can be considered.
110-119
CHRONIC BASOPHILIC LEUKEMIA In addition to his well-established prowess in plasma cell proliferative disorders, Dr Robert A. Kyle is also credited for the first clinical description of chronic basophilic leukemia. 120 More recently, this rare disease was fully characterized, and its features include prominent blood and bone marrow basophilia in the absence of the BCR/ABL gene rearrangement. 121 In the few patients that have so far been described with the disease, clinical presentation included basophil mediator release symptoms including gastrointestinal ulcers, diarrhea, pruritus, and urticaria. The bone marrow typically shows marked dysmegakaryopoiesis with numerous small mononucleated and binucleated forms, prominent basophilia, and lesser degrees of peripheral blood and bone marrow eosinophilia. 121 Granulocyte maturation is usually left-shifted with a slight increase in myeloblasts. The disease is usually aggressive with the potential to transform into AML. Information is limited on aspects of clonality, cytogenetics, and treatment. We recommend therapy similar to that for molecularly undefined CEL (see section entitled CEL, Molecularly Not Defined). lute peripheral blood monocytosis is accompanied by evidence of both effective (myeloproliferative) and ineffective (myelodysplastic) hematopoiesis. The WHO committee on classification of hematological malignancies recently reclassified CMML as an MDS/MPD overlap syndrome requiring (1) a peripheral blood monocyte count greater than 1 × 10 9 /L, (2) the absence of more than 20% blasts in either the peripheral blood or the bone marrow, and (3) the presence of dysplasia in 1 or more myeloid lineages or cytogenetic abnormality or persistent unexplained monocytosis. 2 We prefer to label CMML as atypical MPD but maintain the WHO criteria for diagnosis.
CHRONIC MYELOMONOCYTIC LEUKEMIA
Little is currently known about the primary oncogenic events that lead to CMML. Nonspecific cytogenetic abnormalities are seen in approximately 20% to 30% of patients at diagnosis and include monosomy 7, trisomy 8, and complex abnormalities. [122] [123] [124] [125] Despite earlier speculations, 36 the incidence of TEL/PDGFRB mutation or its cytogenetic counterpart in CMML is very low; 1 of 27 consecutive cases in one series 126 and none of 203 cases in another series. 124 Although not conclusive, FISH-based clonality studies in CMML have suggested pan-myeloid but not lymphoid lineage clonal involvement. 127, 128 Finally, in a series of 119 patients with CMML, JAK2 V617F was detected in only 3% of the patients. 129 Chronic myelomonocytic leukemia is approximately 2-fold more prevalent in men compared with women and primarily affects elderly people with median age at presentation that ranges from 65 to 75 years. 124, 130 Common symptoms and signs of the disease include fatigue, weight loss, fever and night sweats, splenomegaly, and hepatomegaly. Serositis is another CMML characteristic, but relatively infrequent, disease feature and might involve the joints (arthritis), pericardium (pericarditis and pericardial effusion), pleura (pleural effusion), or peritoneum (ascites). 131, 132 The bone marrow is often hypercellular with granulocytic proliferation as the predominant feature. Monocytic proliferation, although invariably present, may be difficult to appreciate without the use of specific cytochemical stains. Dysplasia is usual and may involve 1, 2, or all myeloid lineages.
According to a recent meta-analysis of reported series of CMML, both median survival and median time to transformation into AML (usually M4 or M5) were 1.5 to 2 years. 133 For practical purposes, we consider increased bone marrow blast percentage (>5%), presence of anemia (hemoglobin level <10 g/dL), and presence of abnormal karyotype as the main predictors of shortened survival.
134
At present, hydroxyurea and supportive care (red blood cell and platelet transfusions, erythropoietin) remain the standard of care for most patients with CMML. Further support for such a treatment strategy comes from a recent randomized trial in which hydroxyurea performed better than oral etoposide. 135 Similarly, it is unclear at this time whether other investigational agents (eg, topotecan, 136 combination topotecan and intermediate-dose cytarabine, 137 AML-type induction) 138 are superior to hydroxyurea monotherapy. On the other hand, ASCT is a viable treatment option for transplant-eligible recipients with poor prognostic features. In this regard, in the largest study reported so far, a total of 50 adult patients with CMML underwent ASCT from either related (n=43) or unrelated (n=7) donors. 139 Twentysix patients (52%) died of treatment-related causes. After a median follow-up of 40 months, the 5-year estimated overall and disease-free survival were 21% and 18%, respectively. 139 Whether reduced intensity conditioning ASCT can overcome treatment-related mortality and morbidity in CMML remains to be seen. 140 JUVENILE MYELOMONOCYTIC LEUKEMIA Juvenile myelomonocytic leukemia is primarily a disease of early childhood and is included, along with CMML, in the "MDS/MPD" WHO category of CMD.
2 Both CMML and JMML feature leukocytosis, monocytosis, and hepatosplenomegaly. Additional characteristic features in JMML include thrombocytopenia and elevated fetal hemoglobin levels. 141 Myeloid progenitors display granulocyte-macrophage colony-stimulating factor hypersensitivity in JMML that has been attributed to deregulated RAS/MAPK signaling as a result of mutually exclusive mutations affecting one of the pathway regulatory molecules, including the genes for RAS, PTPN11 (encoding for the nonreceptor protein tyrosine phosphatase, SHP-2, that transmits signals from growth factor receptors to Ras), and NF1 (neurofibromatosis type 1 encoding for neurofibromin protein that inactivates Ras). 142, 143 A third of patients with JMML that is not associated with Noonan syndrome carry PTPN11 mutations, 142, 144 whereas the incidence of NF1 mutations (in patients without neurofibromatosis, type 1) 143 and RAS
145
mutations is approximately 15% to 20% each. The aforementioned molecular information has been exploited in recent clinical trials in JMML that used drugs with the potential to interfere with the RAS signaling pathway. 146 At present, however, the treatment of choice for JMML remains ASCT that results in a 5-year survival of approximately 50%.
147,148
SM, MOLECULARLY NOT DEFINED Mast cell disease is defined as tissue infiltration by morphologically and immunophenotypically abnormal mast cells. It is classified into 2 broad categories, cutaneous mastocytosis and SM. 149, 150 Mast cell disease in adults is usually systemic, and the clinical course can be either indolent or aggressive, depending on the respective absence or presence of impaired organ function. Symptoms and signs of the disease include urticaria pigmentosa, mast cell mediator release symptoms (headache, flushing, lightheadedness, syncope, anaphylaxis, pruritus, urticaria, angioedema, nausea, diarrhea, abdominal cramps), and organ damage (lytic bone lesions, osteoporosis, hepatosplenomegaly, cytopenia). 151 Aggressive SM can be associated with either another MPD or, rarely, mast cell leukemia. 149, 150 In general, life expectancy is nearly normal in indolent SM but significantly shortened in aggressive SM including MPD-associated SM. 149, 152 Molecularly defined SM, associated with either FIP1L1-PDGFRA or KIT mutations, has been discussed in previous sections of the current paper. However, these mutations are not detected in a substantial proportion of adult patients with SM, thus forming the group of patients with molecularly undefined SM. 45 Regardless, diagnosis is based on bone marrow examination that shows clusters of morphologically abnormal spindle-shaped mast cells that are best evaluated with the use of immunohistochemical stains that are specific to mast cells (tryptase, CD117). 153, 154 In addition, we recommend mast cell immunophenotyping in suspected cases to search for aberrant CD25 expression by neoplastic mast cells. 155 Other laboratory findings in SM include increased levels of serum tryptase, histamine, calcitonin, and urine histamine metabolites including methylimidazoleacetic acid and prostaglandins. 151 Patients with either indolent or aggressive SM might experience mast cell mediator release symptoms, which are suboptimally managed by both H-1 and H-2 histamine receptor blockers as well as cromolyn sodium. 156 In addition, patients with a propensity to vasodilatory shock should wear a medical alert bracelet and carry an epinephrine self-injector pen for self administration of subcutaneous epinephrine. 157 Urticaria pigmentosa shows variable response to both topical and systemic corticosteroid therapy. 158 Cytoreductive therapy is not recommended for indolent SM. 159 In aggressive SM, either interferon alfa (starting dosage, 1 million units 3 times weekly) or cladribine (2-hour infusion of 5 mg/m 2 per day for 5 days repeated every 4 weeks for 4 to 6 cycles) is considered firstline therapy and benefits most patients. 51, 52 In contrast, imatinib is ineffective in the treatment of molecularly undefined SM. 160 
UNCLASSIFIED MYELOPROLIFERATIVE DISORDER
The category of UMPD serves to accommodate MPD-or MDS-like disorders that cannot be clearly assigned one of the aforementioned CMD diagnoses. Some cases display features of both MPD and MDS, whereas others mimic CML without the disease-defining BCR/ABL mutation (aka, atypical or BCR/ABL-negative CML). [161] [162] [163] [164] A FrenchAmerican-British Cooperative Group analyzed 51 cases of CML-or CMML-like cases and constructed a statistical model that separates "atypical" CML from both CMML and BCR/ABL-positive CML. 163 Accordingly, atypical CML was characterized by a higher degree of granulocytic dysplasia and a lesser rate of basophilia and monocytosis. However, we favor reserving the term chronic myeloid leukemia to refer to only those cases with detectable BCR/ ABL and encourage the use of the term unclassified myeloproliferative disorders otherwise. Patients with UMPD are managed in a similar fashion to those with either MDS or molecularly undefined atypical MPD. Whether the relatively frequent (25%) JAK2 V617F mutation in UMPD will have therapeutic relevance during future targeted treatments remains to be seen. 165 
CONCLUSION
It is only a matter of time before the molecular underpinnings of all CMD, including atypical MPD, are fully characterized, thus paving the way for a molecular classification system as well as the development of pathogenesistargeted diagnostic and therapeutic approaches. In this regard, the most recent exciting development concerns a novel JAK2 somatic point mutation (a G-C to T-A transversion, at nucleotide 1849 of exon 14, resulting in the substitution of valine to phenylalanine at codon 617; JAK2 V617F ) that was described in both classic and atypical, BCR/ABLnegative MPD. 3, 129, [165] [166] [167] [168] [169] [170] [171] [172] [173] Although the pathogenetic relevance of this mutation remains uncertain at this point, the discovery has provided guidance for both areas of focus for additional pathogenetic studies and development of targeted therapeutics. In the meantime, current diagnostic work-up for atypical MPD should always start with screening, both by cytogenetic and other molecular studies, for therapeutically relevant mutations including BCR/ABL, FIP1L1-PDGFRA, rearrangements involving either FGFR1 or PDGFRB, and KIT
D816V
. In the absence of such well-defined molecular markers, diagnosis is made on the basis of a constellation of clinical, bone marrow histological, cytochemical, chromosomal, and immunophenotypic features. 
